{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T13:29:06Z","timestamp":1781011746229,"version":"3.54.1"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2022,3,28]],"date-time":"2022-03-28T00:00:00Z","timestamp":1648425600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,3,28]],"date-time":"2022-03-28T00:00:00Z","timestamp":1648425600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur Radiol"],"DOI":"10.1007\/s00330-022-08669-8","type":"journal-article","created":{"date-parts":[[2022,3,28]],"date-time":"2022-03-28T14:03:42Z","timestamp":1648476222000},"page":"6536-6544","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Interpretation of 2-[18F]FDG PET\/CT in Hodgkin lymphoma patients treated with immune checkpoint inhibitors"],"prefix":"10.1007","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4280-7825","authenticated-orcid":false,"given":"Guillaume","family":"Manson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amaeshi Chukwunonye","family":"Lemchukwu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatima-Zohra","family":"Mokrane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Egesta","family":"Lopci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Aide","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laetitia","family":"Vercellino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roch","family":"Houot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Dercle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,3,28]]},"reference":[{"key":"8669_CR1","doi-asserted-by":"publisher","unstructured":"Chen R, Zinzani PL, Lee HJ et al (2019) Pembrolizumab in relapsed or refractory Hodgkin lymphoma: two-year follow-up of KEYNOTE-087. Blood. 2019000324. https:\/\/doi.org\/10.1182\/blood.2019000324","DOI":"10.1182\/blood.2019000324"},{"key":"8669_CR2","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1200\/JCO.2017.76.0793","volume":"36","author":"P Armand","year":"2018","unstructured":"Armand P, Engert A, Younes A et al (2018) Nivolumab for relapsed\/refractory classic Hodgkin lymphoma after failure of autologous hematopoietic cell transplantation: extended follow-up of the multicohort single-arm phase II CheckMate 205 Trial. J Clin Oncol 36:1428\u20131439. https:\/\/doi.org\/10.1200\/JCO.2017.76.0793","journal-title":"J Clin Oncol"},{"key":"8669_CR3","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.ejca.2019.04.006","volume":"115","author":"G Manson","year":"2019","unstructured":"Manson G, Mear J, Herbaux C et al (2019) Long-term efficacy of anti-PD1 therapy in Hodgkin lymphoma with and without allogenic stem cell transplantation. Eur J Cancer 115:47\u201356. https:\/\/doi.org\/10.1016\/j.ejca.2019.04.006","journal-title":"Eur J Cancer"},{"key":"8669_CR4","doi-asserted-by":"publisher","first-page":"2496","DOI":"10.1093\/annonc\/mdx341","volume":"28","author":"H Bek\u00f6z","year":"2017","unstructured":"Bek\u00f6z H, Karadurmu\u015f N, Payda\u015f S et al (2017) Nivolumab for relapsed or refractory Hodgkin lymphoma: real-life experience. Ann Oncol 28:2496\u20132502. https:\/\/doi.org\/10.1093\/annonc\/mdx341","journal-title":"Ann Oncol"},{"key":"8669_CR5","doi-asserted-by":"publisher","unstructured":"Manson G, Brice P, Herbaux C et al (2020) Risk of relapse after anti-PD1 discontinuation in patients with Hodgkin lymphoma. Eur J Nucl Med Mol Imaging. https:\/\/doi.org\/10.1007\/s00259-020-05015-2","DOI":"10.1007\/s00259-020-05015-2"},{"key":"8669_CR6","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1038\/nrc2542","volume":"9","author":"R K\u00fcppers","year":"2009","unstructured":"K\u00fcppers R (2009) The biology of Hodgkin\u2019s lymphoma. Nat Rev Cancer 9:15\u201327. https:\/\/doi.org\/10.1038\/nrc2542","journal-title":"Nat Rev Cancer"},{"key":"8669_CR7","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1126\/science.1160809","volume":"324","author":"MGV Heiden","year":"2009","unstructured":"Heiden MGV, Cantley LC, Thompson CB (2009) Understanding the warburg effect: the metabolic requirements of cell proliferation. Science (80-) 324:1029\u20131033","journal-title":"Science (80-)"},{"key":"8669_CR8","doi-asserted-by":"publisher","first-page":"25","DOI":"10.2967\/jnumed.109.067892","volume":"51","author":"M Weiler-Sagie","year":"2010","unstructured":"Weiler-Sagie M, Bushelev O, Epelbaum R et al (2010) 18F-FDG avidity in lymphoma readdressed: a study of 766 patients. J Nucl Med 51:25\u201330. https:\/\/doi.org\/10.2967\/jnumed.109.067892","journal-title":"J Nucl Med"},{"key":"8669_CR9","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.3324\/haematol.2016.141846","volume":"101","author":"A Kumar","year":"2016","unstructured":"Kumar A, Burger IA, Zhang Z et al (2016) Definition of bulky disease in early stage Hodgkin lymphoma in computed tomography era: Prognostic significance of measurements in the coronal and transverse planes. Haematologica 101:1237\u20131243. https:\/\/doi.org\/10.3324\/haematol.2016.141846","journal-title":"Haematologica"},{"key":"8669_CR10","doi-asserted-by":"publisher","first-page":"4508","DOI":"10.1200\/JCO.2012.42.4036","volume":"30","author":"TC El-Galaly","year":"2012","unstructured":"El-Galaly TC, D\u2019Amore F, Mylam KJ et al (2012) Routine bone marrow biopsy has little or no therapeutic consequence for positron emission tomography\/computed tomography-staged treatment-naive patients with Hodgkin lymphoma. J Clin Oncol 30:4508\u20134514. https:\/\/doi.org\/10.1200\/JCO.2012.42.4036","journal-title":"J Clin Oncol"},{"key":"8669_CR11","first-page":"266","volume":"86","author":"G Jerusalem","year":"2001","unstructured":"Jerusalem G, Beguin Y, Fassotte M et al (2001) Whole-body positron emission tomography using 18F-fluorodeoxyglucose compared to standard procedures for staging patients with Hodgkin\u2019s disease. Haematologica 86:266\u2013273","journal-title":"Haematologica"},{"key":"8669_CR12","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","volume":"32","author":"BD Cheson","year":"2014","unstructured":"Cheson BD, Fisher RI, Barrington SF et al (2014) Recommendations for initial evaluation, staging, and response assessment of hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol 32:3059\u20133067","journal-title":"J Clin Oncol"},{"key":"8669_CR13","doi-asserted-by":"publisher","unstructured":"Brice P, de Kerviler E, Friedberg JW (2021) Classical Hodgkin lymphoma. Lancet:6736. https:\/\/doi.org\/10.1016\/S0140-6736(20)32207-8","DOI":"10.1016\/S0140-6736(20)32207-8"},{"key":"8669_CR14","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","volume":"25","author":"BD Cheson","year":"2007","unstructured":"Cheson BD, Pfistner B, Juweid ME et al (2007) Revised response criteria for malignant lymphoma. J Clin Oncol 25:579\u2013586","journal-title":"J Clin Oncol"},{"key":"8669_CR15","doi-asserted-by":"publisher","first-page":"192056","DOI":"10.1148\/radiol.2020192056","volume":"18","author":"F-Z Mokrane","year":"2020","unstructured":"Mokrane F-Z, Chen A, Schwartz LH et al (2020) Performance of CT compared with 18 F-FDG PET in predicting the efficacy of nivolumab in relapsed or refractory Hodgkin lymphoma. Radiology 18:192056. https:\/\/doi.org\/10.1148\/radiol.2020192056","journal-title":"Radiology"},{"key":"8669_CR16","doi-asserted-by":"publisher","unstructured":"Castello A, Grizzi F, Qehajaj D, Rahal D, Lutman F, Lopci E (2019) 18 F-FDG PET\/CT for response assessment in Hodgkin lymphoma undergoing immunotherapy with checkpoint inhibitors. Leuk Lymphoma 60:367\u2013375. https:\/\/doi.org\/10.1080\/10428194.2018.1488254","DOI":"10.1080\/10428194.2018.1488254"},{"key":"8669_CR17","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1016\/j.it.2019.03.003","volume":"40","author":"SM Ansell","year":"2019","unstructured":"Ansell SM (2019) Immunotherapy in Hodgkin lymphoma: the road ahead. Trends Immunol 40:380\u2013386. https:\/\/doi.org\/10.1016\/j.it.2019.03.003","journal-title":"Trends Immunol"},{"key":"8669_CR18","doi-asserted-by":"publisher","unstructured":"Ramchandren R, Domingo-Dom\u00e8nech E, Rueda A et al (2019) Nivolumab for newly diagnosed advanced-stage classic Hodgkin lymphoma: safety and efficacy in the phase II CheckMate 205 Study. J Clin Oncol.19.00315. https:\/\/doi.org\/10.1200\/JCO.19.00315","DOI":"10.1200\/JCO.19.00315"},{"key":"8669_CR19","doi-asserted-by":"publisher","first-page":"2856","DOI":"10.1182\/blood-2018-03-841262","volume":"131","author":"G Manson","year":"2018","unstructured":"Manson G, Herbaux C, Brice P et al (2018) Prolonged remissions after anti-PD-1 discontinuation in patients with Hodgkin lymphoma. Blood 131:2856\u20132859. https:\/\/doi.org\/10.1182\/blood-2018-03-841262","journal-title":"Blood"},{"key":"8669_CR20","doi-asserted-by":"publisher","first-page":"649","DOI":"10.2967\/jnumed.119.232827","volume":"61","author":"A Chen","year":"2020","unstructured":"Chen A, Mokrane F-Z, Schwartz LH et al (2020) Early 18 F-FDG PET\/CT response predicts survival in relapsed or refractory Hodgkin lymphoma treated with nivolumab. J Nucl Med 61:649\u2013654. https:\/\/doi.org\/10.2967\/jnumed.119.232827","journal-title":"J Nucl Med"},{"key":"8669_CR21","doi-asserted-by":"publisher","first-page":"15","DOI":"10.2967\/jnumed.117.193011","volume":"59","author":"L Dercle","year":"2018","unstructured":"Dercle L, Seban R-D, Lazarovici J et al (2018) 18 F-FDG PET and CT scans detect new imaging patterns of response and progression in patients with Hodgkin lymphoma treated by anti\u2013programmed death 1 immune checkpoint inhibitor. J Nucl Med 59:15\u201324. https:\/\/doi.org\/10.2967\/jnumed.117.193011","journal-title":"J Nucl Med"},{"key":"8669_CR22","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1007\/s00262-008-0642-y","volume":"58","author":"AM Di Giacomo","year":"2009","unstructured":"Di Giacomo AM, Danielli R, Guidoboni M et al (2009) Therapeutic efficacy of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with metastatic melanoma unresponsive to prior systemic treatments: clinical and immunological evidence from three patient cases. Cancer Immunol Immunother 58:1297\u20131306. https:\/\/doi.org\/10.1007\/s00262-008-0642-y","journal-title":"Cancer Immunol Immunother"},{"key":"8669_CR23","doi-asserted-by":"publisher","first-page":"3541","DOI":"10.1200\/JCO.2015.61.6870","volume":"33","author":"VL Chiou","year":"2015","unstructured":"Chiou VL, Burotto M (2015) Pseudoprogression and immune-related response in solid tumors. J Clin Oncol 33:3541\u20133543","journal-title":"J Clin Oncol"},{"key":"8669_CR24","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1148\/radiol.2020200443","volume":"297","author":"HJ Park","year":"2020","unstructured":"Park HJ, Kim KW, Pyo J et al (2020) Incidence of pseudoprogression during immune checkpoint inhibitor therapy for solid tumors: a systematic review and meta-analysis. Radiology 297:87\u201396. https:\/\/doi.org\/10.1148\/radiol.2020200443","journal-title":"Radiology"},{"key":"8669_CR25","doi-asserted-by":"publisher","unstructured":"Meignan M, Gallamini A, Meignan M, Gallamini A, Haioun C (2009) Report on the First International Workshop on interim-PET scan in lymphoma. Leuk Lymphoma 50:1257\u20131260. https:\/\/doi.org\/10.1080\/10428190903040048","DOI":"10.1080\/10428190903040048"},{"key":"8669_CR26","doi-asserted-by":"publisher","first-page":"2489","DOI":"10.1182\/blood-2016-05-718528","volume":"128","author":"BD Cheson","year":"2016","unstructured":"Cheson BD, Ansell S, Schwartz L et al (2016) Refinement of the Lugano classification lymphoma response criteria in the era of immunomodulatory therapy. Blood 128:2489\u20132496. https:\/\/doi.org\/10.1182\/blood-2016-05-718528","journal-title":"Blood"},{"key":"8669_CR27","doi-asserted-by":"publisher","unstructured":"Merryman RW, Carreau NA, Advani RH et al (2020) Impact of treatment beyond progression with immune checkpoint blockade in Hodgkin lymphoma. Oncologist 25. https:\/\/doi.org\/10.1634\/theoncologist.2020-0040","DOI":"10.1634\/theoncologist.2020-0040"},{"key":"8669_CR28","doi-asserted-by":"publisher","unstructured":"Grecea M, Marabelle A, Ammari S, Massard C, Champiat S (2020) Managing hyperprogressive disease in the era of programmed cell death protein 1\/programmed death-ligand 1 blockade: a case discussion and review of the literature. Oncologist 25:369\u2013374. https:\/\/doi.org\/10.1634\/theoncologist.2019-0671","DOI":"10.1634\/theoncologist.2019-0671"},{"key":"8669_CR29","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1038\/s41571-018-0111-2","volume":"15","author":"S Champiat","year":"2018","unstructured":"Champiat S, Ferrara R, Massard C et al (2018) Hyperprogressive disease: recognizing a novel pattern to improve patient management. Nat Rev Clin Oncol 15:748\u2013762","journal-title":"Nat Rev Clin Oncol"},{"key":"8669_CR30","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1001\/jamaoncol.2018.3676","volume":"4","author":"R Ferrara","year":"2018","unstructured":"Ferrara R, Mezquita L, Texier M et al (2018) Hyperprogressive disease in patients with advanced non\u2013small cell lung cancer treated with PD-1\/PD-L1 inhibitors or with single-agent chemotherapy. JAMA Oncol 4:1543. https:\/\/doi.org\/10.1001\/jamaoncol.2018.3676","journal-title":"JAMA Oncol"},{"key":"8669_CR31","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/j.it.2019.03.005","volume":"40","author":"T Wartewig","year":"2019","unstructured":"Wartewig T, Ruland J (2019) PD-1 tumor suppressor signaling in T cell lymphomas. Trends Immunol 40:403\u2013414. https:\/\/doi.org\/10.1016\/j.it.2019.03.005","journal-title":"Trends Immunol"},{"key":"8669_CR32","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1038\/nature24649","volume":"552","author":"T Wartewig","year":"2017","unstructured":"Wartewig T, Kurgyis Z, Keppler S et al (2017) PD-1 is a haploinsufficient suppressor of T cell lymphomagenesis. Nature 552:121\u2013125. https:\/\/doi.org\/10.1038\/nature24649","journal-title":"Nature"},{"key":"8669_CR33","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1097\/RCT.0000000000001043","volume":"44","author":"J Liput","year":"2020","unstructured":"Liput J, Guler E, Smith DA et al (2020) Clinical, imaging findings, responses, and outcomes of patients with classical Hodgkin lymphoma and non-Hodgkin lymphoma undergoing immune checkpoint inhibitor therapy: a single-institution experience. J Comput Assist Tomogr 44:619\u2013626. https:\/\/doi.org\/10.1097\/RCT.0000000000001043","journal-title":"J Comput Assist Tomogr"},{"key":"8669_CR34","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.2967\/jnumed.120.242768","volume":"61","author":"R-D Seban","year":"2020","unstructured":"Seban R-D, Schwartz LH, Bonardel G, Dercle L (2020) Diagnosis of hyperprogressive disease in patients treated with checkpoint inhibitors using 18F-FDG PET\/CT. J Nucl Med 61:1404\u20131405. https:\/\/doi.org\/10.2967\/jnumed.120.242768","journal-title":"J Nucl Med"},{"key":"8669_CR35","doi-asserted-by":"publisher","first-page":"2035","DOI":"10.1056\/NEJMc1203984","volume":"366","author":"SM Hiniker","year":"2012","unstructured":"Hiniker SM, Chen DS, Knox SJ (2012) Abscopal effect in a patient with melanoma. N Engl J Med 366:2035\u20132036. https:\/\/doi.org\/10.1056\/NEJMc1203984","journal-title":"N Engl J Med"},{"key":"8669_CR36","doi-asserted-by":"publisher","unstructured":"Wight JC, Hawkes EA, Berlangieri SU, Khor R, Grigg AP (2018) An abscopal effect may augment PD-1 inhibition in refractory classical Hodgkin lymphoma. Leuk Lymphoma 59:2749\u20132751. https:\/\/doi.org\/10.1080\/10428194.2018.1452217","DOI":"10.1080\/10428194.2018.1452217"},{"key":"8669_CR37","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.ejca.2016.06.017","volume":"66","author":"JM Michot","year":"2016","unstructured":"Michot JM, Mazeron R, Dercle L et al (2016) Abscopal effect in a Hodgkin lymphoma patient treated by an anti-programmed death 1 antibody. Eur J Cancer 66:91\u201394. https:\/\/doi.org\/10.1016\/j.ejca.2016.06.017","journal-title":"Eur J Cancer"},{"key":"8669_CR38","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1667\/rr15048.1","volume":"190","author":"Q Qin","year":"2018","unstructured":"Qin Q, Nan X, Miller T et al (2018) Complete local and abscopal responses from a combination of radiation and nivolumab in refractory Hodgkin\u2019s lymphoma. Radiat Res 190:322. https:\/\/doi.org\/10.1667\/rr15048.1","journal-title":"Radiat Res"},{"key":"8669_CR39","doi-asserted-by":"publisher","unstructured":"Bernard-Tessier A, Baldini C, Castanon E et al (2020) Patterns of progression in patients treated for immuno-oncology antibodies combination. Cancer Immunol Immunother 1\u201312. https:\/\/doi.org\/10.1007\/s00262-020-02647-z","DOI":"10.1007\/s00262-020-02647-z"},{"key":"8669_CR40","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.ejca.2017.10.017","volume":"88","author":"M Tazdait","year":"2018","unstructured":"Tazdait M, Mezquita L, Lahmar J et al (2018) Patterns of responses in metastatic NSCLC during PD-1 or PDL-1 inhibitor therapy: comparison of RECIST 1.1, irRECIST and iRECIST criteria. Eur J Cancer 88:38\u201347. https:\/\/doi.org\/10.1016\/j.ejca.2017.10.017","journal-title":"Eur J Cancer"},{"key":"8669_CR41","doi-asserted-by":"publisher","unstructured":"Thompson JA, Schneider BJ, Brahmer J et al (2020) Management of immunotherapy-related toxicities, version 1.2020 featured updates to the NCCN guidelines. J Natl Compr Cancer Netw 18:231\u2013241. https:\/\/doi.org\/10.6004\/jnccn.2020.0012","DOI":"10.6004\/jnccn.2020.0012"},{"key":"8669_CR42","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.ejca.2018.03.006","volume":"96","author":"A Mekki","year":"2018","unstructured":"Mekki A, Dercle L, Lichtenstein P et al (2018) Detection of immune-related adverse events by medical imaging in patients treated with anti-programmed cell death 1. Eur J Cancer 96:91\u2013104. https:\/\/doi.org\/10.1016\/j.ejca.2018.03.006","journal-title":"Eur J Cancer"},{"key":"8669_CR43","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1007\/s00259-019-04310-x","volume":"46","author":"L Dercle","year":"2019","unstructured":"Dercle L, Mokrane F-Z, Schiano de Colella JM et al (2019) Unconventional immune-related phenomena observed using 18F-FDG PET\/CT in Hodgkin lymphoma treated with anti PD-1 monoclonal antibodies. Eur J Nucl Med Mol Imaging 46:1391\u20131392. https:\/\/doi.org\/10.1007\/s00259-019-04310-x","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"8669_CR44","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1007\/s00432-018-2805-3","volume":"145","author":"B Ricciuti","year":"2019","unstructured":"Ricciuti B, Genova C, De Giglio A et al (2019) Impact of immune-related adverse events on survival in patients with advanced non-small cell lung cancer treated with nivolumab: long-term outcomes from a multi-institutional analysis. J Cancer Res Clin Oncol 145:479\u2013485. https:\/\/doi.org\/10.1007\/s00432-018-2805-3","journal-title":"J Cancer Res Clin Oncol"},{"key":"8669_CR45","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1001\/jamaoncol.2017.2925","volume":"4","author":"K Haratani","year":"2018","unstructured":"Haratani K, Hayashi H, Chiba Y et al (2018) Association of immune-related adverse events with nivolumab efficacy in non-small cell lung cancer. JAMA Oncol 4:374\u2013378. https:\/\/doi.org\/10.1001\/jamaoncol.2017.2925","journal-title":"JAMA Oncol"},{"key":"8669_CR46","doi-asserted-by":"publisher","unstructured":"Eggermont AMM, Kicinski M, Blank CU et al (2020) Association between immune-related adverse events and recurrence-free survival among patients with stage III melanoma randomized to receive pembrolizumab or placebo: a secondary analysis of a randomized clinical trial. JAMA Oncol. https:\/\/doi.org\/10.1001\/jamaoncol.2019.5570","DOI":"10.1001\/jamaoncol.2019.5570"},{"key":"8669_CR47","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1007\/s00432-018-2819-x","volume":"145","author":"A Indini","year":"2019","unstructured":"Indini A, Di Guardo L, Cimminiello C et al (2019) Immune-related adverse events correlate with improved survival in patients undergoing anti-PD1 immunotherapy for metastatic melanoma. J Cancer Res Clin Oncol 145:511\u2013521. https:\/\/doi.org\/10.1007\/s00432-018-2819-x","journal-title":"J Cancer Res Clin Oncol"},{"key":"8669_CR48","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/CJI.0000000000000300","volume":"43","author":"F Petrelli","year":"2020","unstructured":"Petrelli F, Grizzi G, Ghidini M et al (2020) Immune-related adverse events and survival in solid tumors treated with immune checkpoint inhibitors: a systematic review and meta-analysis. J Immunother 43:1\u20137. https:\/\/doi.org\/10.1097\/CJI.0000000000000300","journal-title":"J Immunother"},{"key":"8669_CR49","doi-asserted-by":"publisher","unstructured":"Sachpekidis C, Kopp-Schneider A, Hakim-Meibodi L, Dimitrakopoulou-Strauss A, Hassel JC (2019) 18F-FDG PET\/CT longitudinal studies in patients with advanced metastatic melanoma for response evaluation of combination treatment with vemurafenib and ipilimumab. Melanoma Res 29:178\u2013186. https:\/\/doi.org\/10.1097\/CMR.0000000000000541","DOI":"10.1097\/CMR.0000000000000541"},{"key":"8669_CR50","doi-asserted-by":"publisher","unstructured":"Sachpekidis C, Larrib\u00e8re L, Kopp-Schneider A, Hassel JC, Dimitrakopoulou-Strauss A (2019) Can benign lymphoid tissue changes in 18 F-FDG PET\/CT predict response to immunotherapy in metastatic melanoma? Cancer Immunol Immunother 68:297\u2013303. https:\/\/doi.org\/10.1007\/s00262-018-2279-9","DOI":"10.1007\/s00262-018-2279-9"},{"key":"8669_CR51","doi-asserted-by":"publisher","first-page":"e272","DOI":"10.1097\/RLU.0000000000002453","volume":"44","author":"T Nobashi","year":"2019","unstructured":"Nobashi T, Baratto L, Reddy SA et al (2019) Predicting response to immunotherapy by evaluating tumors, lymphoid cell-rich organs, and immune-related adverse events using FDG-PET\/CT. Clin Nucl Med 44:e272\u2013e279. https:\/\/doi.org\/10.1097\/RLU.0000000000002453","journal-title":"Clin Nucl Med"},{"key":"8669_CR52","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s40644-020-00313-2","volume":"20","author":"A Wong","year":"2020","unstructured":"Wong A, Callahan J, Keyaerts M et al (2020) 18F-FDG PET\/CT based spleen to liver ratio associates with clinical outcome to ipilimumab in patients with metastatic melanoma. Cancer Imaging 20:36. https:\/\/doi.org\/10.1186\/s40644-020-00313-2","journal-title":"Cancer Imaging"},{"key":"8669_CR53","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1007\/s00259-018-4171-4","volume":"46","author":"N Aide","year":"2019","unstructured":"Aide N, Hicks RJ, Le Tourneau C et al (2019) FDG PET\/CT for assessing tumour response to immunotherapy. Eur J Nucl Med Mol Imaging 46:238\u2013250. https:\/\/doi.org\/10.1007\/s00259-018-4171-4","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"8669_CR54","doi-asserted-by":"publisher","first-page":"2298","DOI":"10.1007\/s00259-019-04411-7","volume":"46","author":"R-D Seban","year":"2019","unstructured":"Seban R-D, Nemer JS, Marabelle A et al (2019) Prognostic and theranostic 18F-FDG PET biomarkers for anti-PD1 immunotherapy in metastatic melanoma: association with outcome and transcriptomics. Eur J Nucl Med Mol Imaging 46:2298\u20132310. https:\/\/doi.org\/10.1007\/s00259-019-04411-7","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"8669_CR55","doi-asserted-by":"publisher","first-page":"944","DOI":"10.2174\/1568009621666210720143826","volume":"21","author":"R-D Seban","year":"2021","unstructured":"Seban R-D, Synn S, Muneer I et al (2021) Spleen glucose metabolism on [18F]-FDG PET\/CT for cancer drug discovery and development cannot be overlooked. Curr Cancer Drug Targets 21:944\u2013952. https:\/\/doi.org\/10.2174\/1568009621666210720143826","journal-title":"Curr Cancer Drug Targets"},{"key":"8669_CR56","doi-asserted-by":"publisher","first-page":"2309","DOI":"10.1007\/s00259-020-05126-w","volume":"48","author":"R-D Seban","year":"2021","unstructured":"Seban R-D, Champion L, Schwartz LH, Dercle L (2021) Spleen glucose metabolism on [18F]-FDG PET\/CT: a dynamic double-edged biomarker predicting outcome in cancer patients. Eur J Nucl Med Mol Imaging 48:2309\u20132311. https:\/\/doi.org\/10.1007\/s00259-020-05126-w","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"8669_CR57","doi-asserted-by":"publisher","first-page":"2573","DOI":"10.1007\/s00259-020-05103-3","volume":"48","author":"K Prigent","year":"2021","unstructured":"Prigent K, Lasnon C, Ezine E et al (2021) Assessing immune organs on 18F-FDG PET\/CT imaging for therapy monitoring of immune checkpoint inhibitors: inter-observer variability, prognostic value and evolution during the treatment course of melanoma patients. Eur J Nucl Med Mol Imaging 48:2573\u20132585. https:\/\/doi.org\/10.1007\/s00259-020-05103-3","journal-title":"Eur J Nucl Med Mol Imaging"}],"container-title":["European Radiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00330-022-08669-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00330-022-08669-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00330-022-08669-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,16]],"date-time":"2022-08-16T11:15:41Z","timestamp":1660648541000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00330-022-08669-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,28]]},"references-count":57,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2022,9]]}},"alternative-id":["8669"],"URL":"https:\/\/doi.org\/10.1007\/s00330-022-08669-8","relation":{},"ISSN":["1432-1084"],"issn-type":[{"value":"1432-1084","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,28]]},"assertion":[{"value":"28 October 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 February 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 February 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 March 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The scientific guarantor of this publication is Pr Roch Houot.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Guarantor"}},{"value":"The authors of this manuscript declare no relationships with any companies whose products or services may be related to the subject matter of the article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"No complex statistical methods were necessary for this paper.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Statistics and biometry"}},{"value":"No consent was required as this is a review.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"Institutional Review Board approval was not required because this is a review.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"\u2022 review","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Methodology"}}]}}